Are you sure you want to delete this post?
The administrator for the Centers for Medicare and Medicaid Services(CMS) said that the agency is proposing a way of boosting reimbursements for a customized approach called CAR T-Cell Therapy. According to an article I found on the subject, it has revolutionized treatment for patients with hard-to-treat pediatric leukemia and adult lymphoma. This particular cancer therapy is very costly, to say the least. Reimbursements in this area would definitely revolutionize how patients with blood cancers such as these handle their medical bills.
The administrator for CMS said:
The proposed changes are necessary because “Medicare’s antiquated payment systems” have not kept up with the development of “transformative technologies.” She said she is concerned inadequate payments might be prompting hospitals to limit Medicare patients’ access to needed therapies.
"The agency will boost the size of extra payments it makes to help hospitals incorporate new technologies and treatments into their clinics. Medicare now pays 50 percent of the additional costs of these innovative treatments, but is proposing to increase that to 65 percent."
The only drawback I find is that the extra payments are only available for the first few years a new product is out on the market. I'm hoping this is a supplementary part of the proposal. Or one could only hope that the treatment or drugs get cheaper as they age on the market. I think it's a step in the right direction. Perhaps we can narrow the margin in which patients with certain cancers like these have a hard time finding the treatment they really need. Is this a legit next step to change such an antiquated payment system? Or is it not enough?